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Abstract. 
 
Hypertrophic cardiomyopathy is a human 
heart disease characterized by increased ventricular 
mass, focal areas of fibrosis, myocyte, and myofibrillar 
disorganization. This genetically dominant disease can 
be caused by mutations in any one of several contractile 
proteins, including 
 
b
 
 cardiac myosin heavy chain 
(
 
b
 
MHC). To determine whether point mutations in hu-
man 
 
b
 
MHC have direct effects on interfering with fila-
ment assembly and sarcomeric structure, full-length 
wild-type and mutant human 
 
b
 
MHC cDNAs were 
cloned and expressed in primary cultures of neonatal 
rat ventricular cardiomyocytes (NRC) under conditions 
that promote myofibrillogenesis. A lysine to arginine 
change at amino acid 184 in the consensus ATP binding 
sequence of human 
 
b
 
MHC resulted in abnormal sub-
cellular localization and disrupted both thick and thin 
filament structure in transfected NRC. Diffuse 
 
b
 
MHC 
K184R protein appeared to colocalize with actin 
throughout the myocyte, suggesting a tight interaction 
of these two proteins. Human 
 
b
 
MHC with S472V mu-
tation assembled normally into thick filaments and did 
not affect sarcomeric structure. Two mutant myosins 
previously described as causing human hypertrophic 
cardiomyopathy, R249Q and R403Q, were competent 
to assemble into thick filaments producing myofibrils 
with well defined I bands, A bands, and H zones. Coex-
pression and detection of wild-type 
 
b
 
MHC and either 
R249Q or R403Q proteins in the same myocyte showed 
these proteins are equally able to assemble into the sar-
comere and provided no discernible differences in sub-
cellular localization. Thus, human 
 
b
 
MHC R249Q and 
R403Q mutant proteins were readily incorporated into 
NRC sarcomeres and did not disrupt myofilament for-
mation. This study indicates that the phenotype of myo-
fibrillar disarray seen in HCM patients which harbor ei-
ther of these two mutations may not be directly due to 
the failure of the mutant myosin heavy chain protein to 
assemble and form normal sarcomeres, but may rather 
be a secondary effect possibly resulting from the 
chronic stress of decreased 
 
b
 
MHC function.
 
A
 
 
 
sarcomere
 
, the functional unit of muscle, is com-
posed of a precise arrangement of at least 20
known proteins ordered in nearly crystalline fash-
ion. Complex interactions of a few of these proteins,
mainly actin and myosin, produce the force necessary for
muscular contraction (for review see Squire, 1986). The
association of actin and myosin is tightly regulated by the
troponin complex, tropomyosin, and flux of Ca
 
2
 
1
 
 ions. Pro-
ductive muscular contraction is dependent upon proper
spatial relationships of muscle structural proteins within
the sarcomere. Genetic analysis in 
 
Drosophila
 
 and 
 
Cae-
norhabditis
 
 has shown that mutations in several of the sar-
comeric proteins disrupt myofibrillar organization and af-
fect muscle function (for review see Epstein and Bernstein,
1992). However, for most of these mutations the underly-
ing biochemical/functional defect has not been elucidated.
Thick and thin filaments can form independently of one
another, yet apparently equal stoichiometric quantities of
actin and myosin are required for proper sarcomeric order
(Beall et al., 1989).
The discovery that mutations in sarcomeric proteins cause
an inherited form of human heart disease has brought sig-
nificant attention towards understanding muscle protein
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function. Familial hypertrophic cardiomyopathy (HCM)
 
1
 
is an autosomal dominant, genetically heterogeneous heart
disease with variable penetrance and an assortment of
clinical phenotypes ranging from mild syncope to sudden
death. The hallmark of this disease is unexplained left ven-
tricular hypertrophy in which dilation of the ventricular
chamber is absent (Maron, 1988) and an increase in myo-
cyte disarray associated with abnormal myofilament struc-
ture in hearts with HCM is apparent. Genetic mapping has
identified a minimum of six loci which cosegregate with
the disease, any of which can be responsible for the domi-
nant phenotype. The genes identified as responsible for
HCM all encode different structural components of the sar-
comere, 
 
b
 
 myosin heavy chain (
 
b
 
MHC; Geisterfer-Low-
rance et al., 1990), cardiac troponin T, 
 
a
 
 tropomyosin
(Thierfelder et al., 1994), C protein (Bonne et al., 1995;
Watkins et al., 1995
 
a
 
) as well as the cardiac essential and
regulatory myosin light chains (Poetter et al., 1996). Inter-
estingly, mutations in the myosin light chains produce
skeletal muscle defects and are associated with a rare form
of HCM which displays midventricular hypertrophy. How-
ever, the connection between mutations in sarcomeric pro-
teins and the pathogenesis of HCM is not understood.
Mutations in the 
 
b
 
MHC gene are present in 
 
z
 
30% of
the HCM families currently characterized (Watkins et al.,
1995
 
b
 
). Nearly all of the 
 
b
 
MHC mutations reported are in
the S1 head domain and occur at amino acids that are
highly conserved throughout MHC phylogeny (Warrick
and Spudich, 1987; Mornet et al., 1989). The crystal struc-
ture of S1 shows that many of the HCM mutations contrib-
ute to functional or structural domains within the globular
myosin head (Rayment et al., 1995). Reduced function has
been demonstrated for a few of these mutations (Cuda et
al., 1993; Sweeney et al., 1994; Lankford et al., 1995), yet it
remains to be elucidated how decreased myosin function
may lead to the morphological disarray observed in HCM
hearts. The possibility exists that the mutations in 
 
b
 
MHC
are directly responsible for the myofibrillar disarray caus-
ing defective assembly of the mutant protein and/or inter-
ference with the assembly of the wild-type proteins by a
dominant negative function. In this regard, a class of mis-
sense mutations in the S1 portion of 
 
Caenorhabditis
 
 mus-
cle MHC displays dominant phenotypes that dramatically
disrupt sarcomere organization (Bejsovec and Anderson,
1988, 1990). Although none of the 
 
C. elegans
 
 mutations
correspond to those described in HCM, it is possible that
the human 
 
b
 
MHC mutant proteins have a similar deleteri-
ous affect on myofibril assembly and/or structure.
To address this question, we have developed an in vivo
competition assay that will allow the direct evaluation of the
ability of an epitope tagged mutant human cardiac 
 
b
 
MHC
protein to effectively compete with a wild-type 
 
b
 
MHC pro-
tein for assembly into endogenous sarcomeric units in liv-
ing myocardial cells. In this paper we report the cloning
and construction of full length human 
 
b
 
MHC cDNAs en-
coding wild-type and mutant proteins. Expression of these
clones either individually or in combination within tran-
siently transfected primary cultures of neonatal rat ven-
tricular cardiomyocytes (NRC) was used to analyze the ef-
fect of 
 
b
 
MHC mutations on subcellular localization and
myofibril assembly. A missense mutation in the consensus
ATP binding sequence dramatically affected sarcomere
structure, disrupting myofibril assembly at an early stage.
However, 
 
b
 
MHC with either of two HCM mutations, R249Q
or R403Q, assemble normally. This indicates the myofib-
rillar disarray observed in HCM patients may not be the
direct result of mutant contractile proteins altering myofil-
ament assembly. Furthermore, the data presented here
support previous information suggesting that biochemical
defects in the human 
 
b
 
MHC proteins produce physiologi-
cal dysfunction and pathological alterations in the heart.
 
Materials and Methods
 
Isolation of Human 
 
b
 
MHC cDNA Clones
 
A human heart (ventricular) specific cDNA library (Stratagene, La Jolla,
CA) was screened with end labeled oligonucleotide probes derived from
the 
 
b
 
MHC published sequence (Jaenicke et al., 1990; Liew et al., 1990).
End labeling and library screening were performed as per standard proto-
cols (Sambrook et al., 1989). Selected cDNAs were sequenced using cDNA-
sequence–specific primers (synthesized on a Pharmacia LKB Gene As-
sembler Plus; Pharmacia Biotech, Piscataway, NJ) in conjunction with the
Sequenase kit (United States Biochemicals, Cleveland, OH). Restriction
enzymes used for mapping and subcloning were obtained from GIBCO
BRL (Gaithersburg, MD). Site-directed mutagenesis was performed with
the Sculptor kit (Amersham Corp., Arlington Heights, IL) or by PCR as
described by Higuchi et al. (1988). A small portion of the final PCR prod-
uct was excised from the full length product by treatment with appropriate
restriction enzymes and subsequent gel purification (GeneClean; Bio 101,
La Jolla, CA). The small fragment was sequenced in its entirety to confirm
that the only change(s) present were the desired sequence insertion or
mutation. Correct subclones were then used to replace the wild-type se-
quence in the full length 
 
b
 
MHC cDNA. To eliminate the possibility of a
second mutation affecting the K184R phenotype, this construct was made
independently a second time and subsequently tested. There was no dif-
ference in the phenotype observed for both clones with this mutation.
 
Tissue Culture and Transfections
 
Neonatal rat cardiac cells were isolated from hearts of 1–2-d-old neonatal
rats, purified on a discontinuous percoll gradient (Zhu et al., 1991), and
were plated on chamber slides (NUNC, Naperville, IL) coated with lami-
nin (Sigma Chemical Co., St. Louis, MO). After 
 
z
 
24 h the cells were tran-
siently transfected using a modified calcium phosphate method (Chen and
Okayama, 1988) in DME plus 15% serum (10% horse serum, 5% fetal calf
serum). Approximately 3 
 
m
 
g of DNA was used per well for a two-well
chamber slide. The precipitate was allowed to be in contact with the cells
for 12–20 h. After transfection the cells were washed with PBS, changed
to DME with 1% horse serum, 10
 
2
 
4
 
 M phenylephrine, and were subse-
quently cultured for 2–5 d. Alternatively, the washed cells were cultured
in 15% serum (10% horse serum, 5% fetal calf serum) for 2–5 d. No dif-
ference was observed between these two culture conditions.
Nonmuscle cells (CHO) were grown in two-well chamber slides and
were transfected as described for the neonatal rat ventricular myocytes. 48 h
after transfection the cells were fixed in 3% paraformaldehyde and were
immunostained.
 
Antibodies, Immunostaining, and Microscopy
 
For indirect immunofluorescence staining, the cells were washed briefly in
relaxation buffer A (0.1 M KCl, 5 mM EDTA, 1 mM EGTA), fixed in
fresh 3% paraformaldehyde (made in buffer A), neutralized with 50 mM
NH
 
4
 
Cl, and immunostained with the appropriate antibodies. Sequential
staining using two mouse monoclonals as primary antibodies was per-
formed as follows: after incubation with the first primary antibody and
subsequent washing with buffer A, the immunostained cells were incu-
bated with an FITC conjugated goat anti–mouse affinity purified F(ab)
fragment diluted 1:50 for 40 min. Washing in buffer A was followed by the
second primary antibody, applied for 1 h. The second secondary was lissa-
mine rhodamine (LRSC) AffiniPure donkey anti–mouse diluted 1:100.
 
1. 
 
Abbreviations used in this paper
 
: HCM, hypertrophic cardiomyopathy;
MHC, myosin heavy chain; NRC, neonatal rat cardiomyocytes. 
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The anti–rat myosin light chain 2v antibody was produced in our lab by
Dr. S. Kubalak, as previously described (Kubalak et al., 1996). The epi-
tope specific glu–glu (EE) antibody, derived from polyoma virus medium
T antigen, was a generous gift of Dr. G. Walter (University of California,
San Diego, CA) and was used at a 1:50 dilution of hybridoma supernatant.
 
b
 
MHC, 4H3, monoclonal antibody was a generous gift of Dr. J. Leger (In-
stitut National de la Santé et de la Recherche Médicale, Montpellier,
France) and was diluted 1:20. Anti-HA antibody was purchased from
Boehringer Mannheim (Indianapolis, IN) and was diluted 1:10. Antibody
to actin (A20) was a generous gift of Dr. J. Lin (University of Iowa, Iowa
City, IA) and was diluted 1:20. Phalloidin–rhodamine was purchased from
Molecular Probes Inc. (Eugene, OR) and was diluted 1:1,000. Secondary
antibodies conjugated to FITC or LRSC (1:100 to 1:200 dilution) were
purchased from Jackson Laboratories (Bar Harbor, ME). Stained cells
were mounted using gelvitol with 2.5% DABCO (1,4-diazabicyclo-[2.2.2]
octane). Laser scanning confocal microscopy was performed using the
Bio-Rad MRC1024 equipped with LaserSharp software. All confocal pic-
tures were derived from a z-series which has been projected to produce
the final image shown. Composite images were given pseudocolor and
merged in Adobe Photoshop.
 
Results
 
Cloning and Characterization of Wild-type and Mutant 
Myosin cDNAs 
 
A full-length human 
 
b
 
MHC cDNA was constructed from
the overlapping clones using restriction enzyme sites endog-
enous to the 
 
b
 
MHC sequence (Fig. 1). The reconstructed
full-length cDNA was completely sequenced on both strands
to ensure that no mutations occurred in the encoded wild-
type protein. Small portions of the wild-type 
 
b
 
MHC cDNA
were used as templates to generate nucleotide changes en-
coding desired missense mutations as well as the insertion
of epitope tags. These fragments were sequenced to en-
sure the only change present was the preferred mutation
and were subsequently exchanged into the full length
cDNA. The resulting clones were sequenced across any re-
striction sites used during construction to ensure the de-
sired mutation was the only change present. The open
reading frame of all the 
 
b
 
MHC clones was confirmed via
in vitro transcription and translation (data not shown).
An epitope tag was inserted in the NH
 
2
 
-terminal region
of human 
 
b
 
MHC to facilitate detection of exogenous pro-
tein in transfected NRC. Exogenous 
 
b
 
MHC proteins con-
taining either haemaglutinin (HA-1 
 
5
 
 YPYDVPDYA;
Wilson et al., 1984) or glu–glu (EE 
 
5
 
 EEYMPME; Grus-
senmeyer et al., 1985) epitopes were specifically recognized
by their respective monoclonal antibodies in transiently
transfected NRC (Fig. 2). Each epitope was positioned be-
tween amino acids 3 and 4 of the 
 
b
 
MHC molecule, a do-
main with no ascribed function. As noted in previous stud-
ies, the crystal structure of the myosin S1 head reveals that
the NH
 
2
 
 terminus is free in solution, existing as a random
coil on the surface molecule (Rayment et al., 1993
 
a
 
,
 
b
 
),
making this region a good target for the insertion of short
sequences. The exogenous 
 
b
 
MHC protein was incorpo-
rated into myofibrils in a pattern indistinguishable from
the endogenous MLC2v (data not shown), a molecule
known to bind MHC.
Four missense mutations were generated in the 
 
b
 
MHC
coding sequence via PCR (see Materials and Methods).
Two of the 
 
b
 
MHC mutations generated were based upon
corresponding mutants that remove functions of the 
 
Dictyo-
stelium
 
 MHC II. The lysine at amino acid 185 in 
 
Dictyoste-
lium
 
 MHC is in the ATP binding pocket (Fisher et al.,
1995), and mutation of this amino acid to arginine blocks
ATP exchange of 
 
Dictyostelium
 
 MHC resulting in a “rigor-
like” molecule (Spudich, J., personal communication). The
second mutation is a serine to valine change at amino acid
472 in human 
 
b
 
MHC. 
 
Dictyostelium
 
 myosin with this mu-
tation has slightly higher than normal actin activated ATP-
ase yet in an in vitro motility assay this myosin can move
F-actin at only 10% of the rate for wild-type MHC (Rup-
pel and Spudich, 1996). If actin motility is a requirement
for sarcomeric assembly, then 
 
b
 
MHC protein with this
mutation may be expected to disrupt myofilament struc-
ture. The other two changes, R249Q and R403Q, are
representative of the class of 
 
b
 
MHC mutations found as-
sociated with human hypertrophic cardiomyopathy (Geis-
terfer-Lowrance et al., 1990; Rosenzweig et al., 1991). In
families with these two mutations the disease has high
penetrance and a high incidence of sudden death (Epstein
et al., 1992; Watkins et al., 1992). Furthermore, the R403Q
Figure 1. Cloning and construction of human bMHC cDNA ex-
pression plasmids. (A) The three overlapping cDNA clones
(lcDNA4,  13, and 10) used for construction of the 6-kbp, full-
length human bMHC cDNA are shown below the representation
of the full-length cDNA (bMHC cDNA). The restriction sites
SmaI (S), BamHI (B), and AatII (A) were used to assemble the
full-length clone. Subclones KS59, c13-59, and c13-M were used to
insert the epitope tag sequences or for generation of the mutant
codons. Also listed are the full-length, epitope tagged clones used.
(B) Single letter amino acid sequence of wild-type myosin from
several species are compared. The numbering is based upon the
published human bMHC sequence (Liew et al., 1990). The un-
derlined area is involved in ATP binding. 1, human bMHC; 2,
chick sarcomeric MHC (Molina et al., 1987); 3, rat embryonal sar-
comeric MHC (Strehler et al., 1986); 4, Ceanorhabditis elegans MHC
A (Karn et al., 1983); 5, chick smooth muscle MHC (Yanagisawa
et al., 1987); 6, Dictyostelium discoideum (Warrick et al., 1986); 7,
Acathamoeba castellanii myosin II (Hammer et al., 1987). 
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mutant protein has been shown to display defective con-
tractile function in a variety of in vitro assays (Cuda et al.,
1993; Sweeney et al., 1994; Lankford et al., 1995).
It is possible that insertion of an epitope tag or muta-
tions at specific amino acids may render the 
 
b
 
MHC mole-
cule unstable once expressed in cultured cells. However,
transiently transfected cultures of COS cells immuno-
stained with either 4H3 (anti-
 
b
 
MHC) or the epitope spe-
cific antibodies show detectable levels of 
 
b
 
MHC protein in
 
z
 
25% of the cells for all constructs (data not shown). Fur-
thermore, the frequency of transfection in NRC is the
same for all of the 
 
b
 
MHC expression plasmids (
 
<
 
1% of
NRC was transfected). Taken together, these studies indi-
cate that the epitope tagged wild-type and mutant proteins
were synthesized at comparable levels.
 
Epitope Tagged Wild-type Human 
 
b
 
MHC Assembles in 
a Normal Sarcomeric Pattern in Transfected Neonatal 
Rat Cardiomyocytes
 
Transfected NRC display two distinct classes of phenotype
relevant to the organization of the myofibrils in immuno-
stained cells. One third of the cells display highly orga-
nized myofibrils having well defined sarcomeres identifiable
by clear H zones, A bands, and I bands. The remaining
transfected cells were not well developed or were too faint
to be analyzed. Both classes of cellular phenotype were
observed in nontransfected as well as in transiently trans-
fected NRC fixed and stained for either endogenous or ex-
ogenous myofibrillar proteins. NRC cultures exposed to
calcium phosphate transfection with the backbone vector
pCB6 produce 
 
z
 
40% of the cells filled with highly orga-
nized myofibrils. Cells were only scored if some level of
sarcomeric organization was present. This eliminated con-
taminating fibroblasts from the data set.
Human 
 
b
 
MHC protein accumulates and was detectable
in NRC transiently transfected with the expression con-
structs containing the 
 
b
 
MHC epitope tagged cDNA. In
transfected NRC, the human wild-type bMHC protein
tagged with either EE or HA epitopes assembled into
highly ordered sarcomeres in cells with organized myofila-
ments (Fig. 2). Ordered myofibrils containing exogenous
human bMHC have defined H zones in addition to A
band periodicity complementary to thin filament staining
within the same cell. Clearly defined H zones visible in
cells immunostained for human bMHC showed that the
globular head of the tagged myosin was excluded from the
H zone which indicated that these thick filaments have
normal structure. This result was similar to the previously
described distribution of epitope tagged myosin light chain
(Soldati and Perriard, 1991), which decorated the A band
and was excluded from the H zone, a region devoid of my-
osin heads. The thick filament marker myomesin was found
at the M line in mature myofibrils containing wild-type hu-
man bMHC (data not shown). Furthermore, the staining
pattern of human bMHC was coincident with endogenous
MHC as well as exogenous epitope tagged myosin light chain
(data not shown). Similar to the control cultures, endoge-
nous thin and thick filament markers detected in trans-
fected cells displayed the same degree of organization ob-
Figure 2. Epitope tagged wild-type human bMHC protein assembles into normal myofibrils in transiently transfected NRC. Cells were
transfected with plasmids containing the wild-type human bMHC cDNA tagged with either the EE (A–C) or HA (D–F). The cells were
stained for the presence of actin filaments using rhodamine–phalloidin (A and C) and were costained with the anti-EE (B) or anti-HA (E)
specific antibodies. Sarcomeres containing human bMHC have well defined A bands (a), I bands (i), and M lines (m). The composite
images (C and F) show that the exogenous bMHC (green) fills the A band, except the H zone as expected, in a pattern that is comple-
mentary and partially overlapping with F-actin (red, C and F). Bar, 20 mm (inset enlarged 33).Becker et al. bMHC Mutations: Effects on Sarcomere Structure 135
served for the exogenous wild-type protein (Table I). These
data indicate that the exogenous human bMHC protein
assembled normally into sarcomeres in transfected NRC,
and the presence of the glu–glu or HA epitope tag be-
tween amino acids 3 and 4 did not inhibit this process nor
disrupt sarcomeric organization.
The K184R Mutation Disrupts Sarcomeric Structure in 
Transfected NRC
The K184R mutation in bMHC resulted in a severe alter-
ation in the subcellular localization of this mutant protein
in transfected cardiomyocytes (Fig. 3). The distribution of
K184R protein was visualized as diffuse and somewhat
uniform throughout the cell or occurred as cable-like struc-
tures. Alternatively, K184R accumulated as brightly stain-
ing globules of various size. NRC with large amounts of
K184R protein (i.e., stain very brightly for this molecule)
were small and irregularly shaped with many pointed
lamellipodia (data not shown). As seen in Fig. 3 B, K184R
mutant protein formed cable-like structures similar to those
described as the premyofibril (Rhee et al., 1994). In this
same cell, endogenous MHC (Fig. 3 A) displayed nearly
complete loss of sarcomeric organization. The presence of
K184R bMHC in cardiomyocytes caused disorganization
of endogenous myomesin (Fig. 3, C and D), indicating that
thick filament structure is disturbed. Thin filament order
was also disrupted in cells expressing K184R (Fig. 3, E
and F). In a series of experiments, .2,000 individual cells
successfully transfected with K184R were analyzed by im-
munostaining. In more than half of these cells sarcomeric
organization of thick or thin filament markers was com-
pletely absent. The remaining K184R positive cells con-
tained few sarcomeres, except for rare cells in which the
entire cell volume was filled with highly organized myo-
fibrils (Table I). In NRC with a few recognizable myofila-
ments, K184R bMHC sometimes appeared to decorate
thin filaments or occurred in A band regions, albeit in a
sporadic pattern that never filled the entire sarcomere.
Even though organized phalloidin staining was lost in
many cardiomyocytes with K184R, G actin was readily de-
tectable (Fig. 4). The scattered distribution of K184R pro-
tein within the cell appears to colocalize with G actin, indi-
cating that these molecules may be in close association
with one another.
Mutations at Amino Acids 249, 403, and 472 Do Not 
Alter MHC Assembly
There was no detectable difference in the distribution of
phenotypes comparing expression of wild-type bMHC with
the three bMHC mutations R249Q, R403Q, or S472V in
NRC. All three of these mutant proteins assembled into
extremely organized myofibrils (Fig. 5) at the same fre-
quency as observed for the wild-type bMHC protein (Ta-
ble I). R249Q, R403Q, and S472V mutant proteins assem-
bled into A band regions as defined via costaining for
endogenous myofilament proteins (Figs. 5 and 6). This re-
sult indicated that the three mutants are readily incorpo-
rated into thick filaments, and such inclusion did not pro-
Table I. Morphology of Transfected NRC
Transfected DNA*
Percentage of cells with organized myofibrils
Epitope Actin Myomesin
pCB6 n.a.‡ 40§ 40§
Wild-typei 33 100 100
K184R 0 1.1 0.8
R249Q 32 100 100
R403Q 34 100 100
S472V 33 100 100
*For all DNAs transfected, at least 2,000 cells were scored over several different
transfected cultures.
‡n.a., not available.
§Since transfected cells are not identifiable for the control backbone vector, pCD6,
NRC were randomly scored for endogenous F-actin (via rhodamine–phalloidin) or
myomesin (B4 antibody).
iFor the epitope tagged constructs only immunopositive cells were counted. The num-
bers are presented as percentage of transfected NRC, which display fully organized
myofilaments as detected by indirect immunofluorescence. Epitope specific antibod-
ies identify the exogenous bMHC protein. In transfected NRC with highly organized
myofilaments, the percentage of highly ordered endogenous myofibril markers is also
given.
Figure 3. Expression of K184R bMHC in NRC disrupts myo-
fibril assembly. NRC transfected with the human bMHC K184R
plasmid were stained for with the anti-EE epitope specific anti-
body (B, D, and F). These cells were costained with anti-bMHC
(A), anti-myomesin (C), or rhodamine–phalloidin (E). Sequen-
tial staining with two primary monoclonal antibodies is described
in Materials and Methods. Bar, 20 mm.The Journal of Cell Biology, Volume 137, 1997 136
Figure 4. K184R protein colocalizes with actin. A transfected
NRC expressing K184R was costained with monoclonal antibody
A20 (anti-actin, A) and the epitope specific antibody (anti-EE,
B). The composite image (C) shows the high degree of colocaliza-
tion of these two proteins throughout the cell. Bar, 20 mm. Figure 5. S472V as well as hypertrophic cardiomyopathy mutants
R249Q and R403Q assemble normally and do not disrupt myo-
fibril structure. Cells transfected with R249Q (A and B), R403Q
(C and D), or S472V (E and F) were stained for the presence of
exogenous myosin with the epitope specific antibody (B, D, and
F) and with rhodamine–phalloidin (A, C, and E). Bar, 20 mm.
Figure 6. Thick filaments containing R403Q have normal organization within the sarcomere. NRC transfected with human R403Q plasmid
were costained for exogenous bMHC (B) with the epitope specific antibody and myomesin (A). The merged image (C) shows that myo-
mesin staining is completely localized to the M-line, indicating normal thick filament and sarcomere structure. Bars: (A) 20 mm; (in-
set), 5 mm.
duce an observable defect in sarcomere organization. Unlike
the K184R mutant there was little excess accumulation or
abnormal subcellular localization of the R249Q, R403Q,
or S472V molecules even in cells with little sarcomericBecker et al. bMHC Mutations: Effects on Sarcomere Structure 137
same transfected cell provided a sensitive measure of de-
tecting minor differences in subcellular localization of the
two proteins. Utilization of two different epitopes inserted
at the same location within the bMHC sequence facilitated
immunostaining of both mutant and wild-type bMHC pro-
teins within the same cell. However, the two epitopes that
were useful in the bMHC context were both recognized by
mouse monoclonal antibodies. Therefore a sequential stain-
ing procedure was used to detect signal specific to each
primary antibody (see Materials and Methods). Fig. 7, A
and B shows that little or no bleed through signal was de-
tected in NRC expressing only one wild-type bMHC con-
struct that was stained with both epitope specific antibod-
ies. In cotransfected cells, both wild-type constructs were
observed, and as would be expected, the subcellular local-
ization was identical for the two wild-type proteins present
within the same cell (Fig. 7, C and D). Both proteins were
coincorporated into A bands in a pattern that was comple-
mentary to thin filament staining.
Coexpression of wild-type bMHC with either R249Q,
R403Q, or S472V showed that the assembly characteristics
of the mutant proteins are equivalent to the wild-type mol-
ecule. All three mutant proteins coassembled into thick fil-
aments with the same localization as the wild-type bMHC
within the same cell (Fig. 7, E and F). There was no abnor-
mal distribution or accumulation of mutant in relation to
wild-type bMHC in NRC expressing these human pro-
teins. In contrast, coexpression of K184R disrupts the sar-
comeric organization of wild-type human bMHC within
the same cell (data not shown).
Discussion
In this paper we describe an in vivo system that should
prove useful in the molecular dissection of structure–func-
tion relationships between specific residues in contractile
proteins and their role in myofibrillar assembly in cardiac
muscle cells. The in vivo competition assay can determine
the sorting characteristics of individual contractile protein
isoforms, elucidating subtle differences in subcellular lo-
calization within the cardiomyocyte (Komiyama et al., 1996).
As an initial model system we have focused on human car-
diac bMHC proteins since point mutations in this protein
are implicated as causative in hypertrophic cardiomyopa-
thy. Furthermore, since MHC are highly conserved, in-
sights from studies of invertebrate and nonmuscle myosins
can be analyzed for effects in mammalian cells.
Full length cDNAs expressed bMHC protein when tran-
siently transfected into primary cultures of neonatal rat
ventricular cardiomyocytes. The distribution of the wild-
type human protein is not the result of sticking to myofila-
ments, based upon the observed highly ordered nature of
the immuno-stained sarcomeres containing human bMHC.
Thick filaments containing human bMHC are normal in
structure based upon the A band localization and the dis-
tribution of myomesin staining. Furthermore, the lack of
any fluorescent signal found within the H zone strongly
suggests the exact incorporation of human bMHC into
thick filaments. Previous studies have shown that a trun-
cated form of MHC containing the S1 and S2 domains does
not incorporate into sarcomeres in a defined pattern (John-
son et al., 1988), making it unlikely that a premature stop
Figure 7. Coexpression of both mutant and wild-type bMHC
molecules detects no differences in subcellular localization of the
two exogenous proteins. NRC were cotransfected with both wild-
type and mutant expression plasmids, each tagged with a differ-
ent epitope. Sequential staining (see Materials and Methods) al-
lows detection of each protein within the same cell. A and B show
a cardiomyocyte transfected with Hnwt only. This cell was immu-
nostained with anti-HA, goat anti–mouse–FITC (F(ab)), and anti-
EE and then donkey anti–mouse–LRSC. A shows the anti-HA
specific staining (FITC channel), and B shows the LRSC channel,
indicating that the anti-EE antibody does not crossreact, and
minimal signal bleed through occurs under these conditions. Us-
ing anti-EE to detect Tnwt, the same lack of crossreactivity is ob-
served when costaining with anti-HA (data not shown). Expres-
sion and detection of both Hnwt (C) and Tnwt (D) in the same
cell shows identical subcellular localization for both proteins. The
TnR403Q mutant (F) also shows identical distribution to Hnwt
bMHC (E) when coexpressed in the same cell. Similar results are
obtained when coexpressing either R249Q or S472V with wild-
type bMHC. The type of epitope does not affect the outcome of
this experiment. Bars: (A, C, and E) 20 mm; (E and inset) 5 mm.
structure. These three mutant proteins always colocalized
with the endogenous MHC in transfected cells.
Coexpression of Mutant and Wild-type bMHC in the 
Same Cell
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codon is present in the bMHC cDNAs expressed in the
current studies.
A critical aspect of this in vivo, dual epitope competition
assay is that the presence of the EE or HA epitopes does
not affect the assembly of the human bMHC molecule
into normal sarcomeres of neonatal rat cardiomyocytes.
Slightly more than one-third of the NRC transfected with
either wild-type epitope tagged construct is filled with
highly ordered myofibrils which have incorporated the ex-
ogenous protein throughout their length. This is nearly the
same number of highly organized cells observed in NRC
cultures transfected with the backbone vector. NRC trans-
fected with the epitope tagged myosin light chain construct,
MLC3f-vsv, also show a similar pattern in which approxi-
mately one third of the transfected cells have perfectly or-
dered myofibrils throughout the cell (data not shown). It
should be noted that previous studies have demonstrated
that the epitope tag on MLC3f-vsv does not affect subcel-
lular localization of this molecule in cultures of micro-injected
adult rat (Soldati and Perriard, 1991) or in transfected NRC
(Komiyama et al., 1996).
A point mutation in the ATP binding domain of human
b cardiac MHC acts as a dominant negative on myofila-
ment structure. The subcellular localization of human
bMHC protein in transfected NRC is dramatically af-
fected by the K184R mutation. The corresponding mutant
in  Dictyostelium MHC (K185R) binds actin “normally”
but will not release in the presence of ATP (Spudich, J.,
personal communication). In vivo the Dictyostelium mu-
tant can form thick filaments, however the mutant-con-
taining cells have the same phenotype as cells in which the
myosin gene is deleted. The K184R mutation is located in
the consensus nucleotide binding sequence (GlyXXXXGly-
Lys; Walker et al., 1982). The lysine in this sequence con-
tributes to nucleotide binding via neutralization of one of
the phosphate groups as proposed from the crystal struc-
ture of two GTP binding proteins, EF-Tu and Ha-ras (Jur-
nak, 1985; Pai et al., 1989). The inability to hydrolyze or
bind nucleotide has been described for mutations in other
amino acids within the ATP binding consensus in several
proteins such as ras (Clanton et al., 1987), herpes virus thy-
midine kinase (Liu and Summers, 1988), and Escherichia
coli adenylate kinase (Reinstein et al., 1988). Since the nu-
cleotide binding sequence is so highly conserved it would
be predicted that the K184R mutation in the human
bMHC protein is a “rigor-like” molecule which binds
strongly to actin, resulting in the inability to complete the
energy transduction cycle. This is consistent with the ob-
served mutant myosin distribution as well as the colocal-
ization of human K184R and endogenous actin. In vitro
analysis should elucidate the biochemical characteristics of
this mutant myosin.
Human K184R bMHC may be incorporated into thick
filaments in transfected NRC however sarcomeric organi-
zation is disrupted in these cells. A similar effect occurs
when cytoplasmic actins are over expressed in cardiomyo-
cytes leading to the decay of thin filaments (von Arx et al.,
1995). In contrast to the K184R mutant, cardiac cells con-
taining cytoplasmic actin maintain the framework of the
myofibril including Z lines, A bands, and M lines. Some
sarcomeric assemblages can be found in K184R expressing
NRC, however the predominant phenotype for K184R-
positive cardiomyocytes is the lack of thick and thin filament
organization (Figs. 3 and 4). This suggests a dominant neg-
ative action for the mutant K184R myosin. Mutations in
the glycine residues of the consensus ATP binding sequence
in C. elegans MHC B are dominant, disrupting thick fila-
ment assembly and muscle function (Bejsovec and Ander-
son, 1988, 1990). Thin filament number and organization
are normal in these animals. Only small amounts of the
mutant MHC B protein accumulates in the body wall mus-
cles, which may account for the presence of thin filaments.
To our knowledge this is the first report of a myosin muta-
tion, K184R, that destroys the structure of both thick and
thin myofilaments.
Sarcomeric disorder in NRC expressing K184R may be
the result of blocking nascent myofilament assembly. K184R
can form short strings of cable-like structures (Fig. 3) simi-
lar to the phenotype of loosely aligned MHC filaments
found in developing sarcomeres (Lu et al., 1992). Myo-
mesin, which is found only in mature myofibrils (Lin et al.,
1994), is not associated with K184R bMHC protein out-
side of organized sarcomeres. In cells costained for epi-
tope tagged bMHC and actin, the K184R mutant colocal-
izes with actin throughout the cell (Fig. 4). This suggests
that premyofibril thin filaments (Rhee et al., 1994), or I-Z-I
structures (Schultheiss et al., 1990), are present in associa-
tion with the mutant myosin that may be irreversibly
bound to actin, and this aggregation blocks the maturation
of the myofibril. Alternatively, K184R may destroy the cy-
toarchitecture after incorporation into sarcomeric thick fil-
aments. It is possible that both nascent assembly is blocked
and the destruction of myofilaments is occurring in the
presence of K184R. The abnormal distribution of K184R
in transfected NRC validates the use of this system to ex-
plore sequence-specific requirements on myosin assembly
through single amino acid changes created in vitro.
The S472V change does not disrupt assembly of human
bMHC, documenting the specificity of the effect of the
K184R mutation on sarcomeric assembly. The correspond-
ing Dictyostelium mutant myosin, S465V, has normal actin
binding and actin activated ATPase activities yet moves
actin filaments at only 10% of the rate of wild-type MHC
(Ruppel and Spudich, 1996). This amino acid is part of a
random coil that is highly conserved in all myosins and
which connects the upper and lower domains of the 50-kD
fragment in the myosin head (Rayment et al., 1993a). It is
thought that movement of these two domains occurs dur-
ing the transition from weak to strong actin binding, which
may decrease affinity for the products of ATP hydrolysis
thus initiating the power stroke (Rayment et al., 1993b).
Dictyostelium myosin with this mutation partially rescues
the myosin null phenotype and has increased basal ATP-
ase activity yet has severely impaired ability to mobilize
actin filaments in vitro (Ruppel and Spudich, 1996). It is
plausible that a similar effect on bMHC function is pro-
duced by the S472V human bMHC mutation, which would
suggest that productive acto–myosin interaction is not re-
quired for sarcomere assembly. Alternatively, mutation of
this highly conserved amino acid does not alter function in
the human bMHC protein.
In contrast to the K184R ATP binding site mutation, hy-
pertrophic cardiomyopathy mutations, R249Q and R403Q,
in human bMHC display normal assembly and have noBecker et al. bMHC Mutations: Effects on Sarcomere Structure 139
dominant negative effects on sarcomeric structure. The
subcellular localization of these two proteins is coincident
with endogenous thick filament markers myomesin, MHC
and myosin light chain. In the cotransfection assay HCM
mutant MHCs colocalized with wild-type human bMHC,
and both proteins assembled into structurally normal myo-
filaments. This is consistent with the observation for aMHC
R403Q/1 mice in which mutant aMHC accumulates nor-
mally and cardiac dysfunction precedes histopathologic
changes (Geisterfer-Lowrance et al., 1996). It is unclear,
however, why Marian et al. (1995) have observed sarco-
mere disarray when expressing human bMHC R403Q in
adult feline cardiomyocytes. These authors used an adeno-
viral vector to infect cultured adult cardiomyocytes and
described sarcomere disorganization in cells 5 d after be-
ing exposed to high MOI of virus containing bMHC cDNA
under the control of the CMV promoter. Marian et al.
(1995) are unable to show that bMHC protein is incorpo-
rated into sarcomeres of infected cells. Furthermore, adult
rat cardiomyocytes dedifferentiate with prolonged expo-
sure to culture conditions (Messerli et al., 1993), and this
may also be the case for the feline system. Prolonged cul-
ture of NRC transfected with our human bMHC con-
structs does not change the observations presented and,
expression of our R403Q construct in regenerating adult
rat cardiomyocytes does not interfere with normal myofil-
ament structure (data not shown). However, it is possible
that myofibrils in adult feline myocytes are more sensitive
to disruption by the R403Q mutant protein. In addition,
the NRC system may not accurately mimic the mechanical
load found in vivo which may be necessary to produce dis-
array.
The data presented in this paper support the interpreta-
tion that a decrease in bMHC function is the primary de-
fect in the etiology of hypertrophic cardiomyopathy. These
results are consistent with the idea that MHC functional
insufficiency is the primary stimulus for the hypertrophic
cardiomyopathy phenotype. Therefore, compensatory hy-
pertrophy and sudden death may be secondary responses
to chronic decreased contractile function. R403Q bMHC
protein purified from HCM patients has impaired ability
to mobilize actin filaments in vitro (Cuda et al., 1993), and
skeletal muscle fibers from such patients have reduced
power output as well as decreased unloaded maximal ve-
locity of shortening (Lankford et al., 1995). Decreased
functional capabilities have also been observed for other
HCM bMHC mutations. Future studies employing analy-
sis of single cell function in live transfected NRC should
address the relationship between the biochemical defect in
human bMHC and its effect on contractility.
It is not necessary to propose a poison effect of the
bMHC molecule on the thick filament, as a functional in-
sufficiency would not interfere with the wild-type bMHC
present in HCM patients, yet could still present the stimu-
lus for hypertrophy, which is the hallmark of this disease.
Transgenic mice overexpressing oncogenic ras in the heart
have ventricular hypertrophy, selective diastolic dysfunc-
tion (Hunter et al., 1995), increased systolic function, myo-
cyte disarray, fibrosis, and increased juvenile mortality
(Gottshall et al., 1997). This suggests that chronic stimula-
tion of a second messenger system in the heart produces
all the overt characteristics of hypertrophic cardiomyopa-
thy in humans caused by mutations in sarcomeric proteins.
The data presented in this paper suggest that cellular dys-
morphology is also secondary to biochemical dysfunction
of the sarcomere producing decreased heart function.
The authors are very much indebted to Mahmoud Itani for excellent tech-
nical assistance in preparation of neonatal rat cardiomyocytes. The au-
thors thank the Institute for Biomedical Engineering Confocal and Imag-
ing Core for the use of the confocal microscope. We also thank Drs.
Sanford Bernstein, Pieter Doevendans, Peter Gruber, Kirk Knowlton, and
Howard Rockman for discussions and critical reading of the manuscript.
The Core facility is supported by the Whittaker Foundation Develop-
ment Award (Grants Section). K.D. Becker is supported by an individual
National Research Service Award from the National Institutes of Health.
This work was supported by funds to K.R. Chien from the National Insti-
tutes of Health/National Heart, Lung, and Blood Institute (1 RO1 HL51549;
PO1 HL46345; HL53773; 1 RO1 Hl 55926) and American Heart Associa-
tion (HL 91-022170).
Received for publication 14 October 1996 and in revised form 14 January
1997.
References
Beall, C.J., M.A. Sepanski, and E.A. Fyrberg. 1989. Genetic dissection of
Drosophila myofibril formation: effects of actin and myosin heavy chain null
alleles. Genes Dev. 3:131–140.
Bejsovec, A., and P. Anderson. 1988. Myosin heavy-chain mutations that dis-
rupt Caenorhabditis elegans thick filament assembly. Genes Dev. 2:1307–
1317.
Bejsovec, A., and P. Anderson. 1990. Functions of the myosin ATP and actin
binding sites are required for C. elegans thick filament assembly. Cell. 60:
133–140.
Bonne, G., L. Carrier, J. Bercovici, C. Cruaud, P. Richard, B. Hainque, M.
Gautel, S. Labeit, M. James, J. Beckmann, et al. 1995. Cardiac myosin bind-
ing protein-C gene splice acceptor site mutation is associated with familial
hypertrophic cardiomyopathy. Nat. Genet. 11:438–440.
Chen, C.A., and H. Okayama. 1988. Calcium phosphate-mediated gene trans-
fer: a highly efficient transfection system for stably transforming cells with
plasmid DNA. Biotech. 6:632–638.
Clanton, D.J., Y.Y. Lu, D.G. Blair, and T.Y. Shih. 1987. Structural significance
of the GTP-binding domain of ras p21 studied by site-directed mutagenesis.
Mol. Cell. Biol. 7:3092–3097.
Cuda, G., L. Fananapazir, W.-S. Zhu, J.R. Sellers, and N.D. Epstein. 1993. Skel-
etal muscle expression and abnormal function of b-myosin in hypertrophic
cardiomyopathy. J. Clin. Invest. 91:2861–2865.
Epstein, H.F., and S.I. Bernstein. 1992. Genetic approaches to understanding
muscle development. Dev. Biol. 154:231–244.
Epstein, N.D., G.M. Cohn, F. Cyran, and L. Fananapazir. 1992. Differences in
clinical expression of hypertrophic cardiomyopathy associated with two dis-
tinct mutations in the b-myosin heavy chain gene. J. Clin. Invest. 86:345–352.
Fisher, A.J., C.A. Smith, J. Thoden, R. Smith, K. Sutoh, H.M. Holden, and I.
Rayment. 1995. Structural studies of myosin/nucleotide complexes: A re-
vised model for the molecular basis of muscle contraction. Biophys. J. 68:
19s–28s.
Geisterfer-Lowrance, A.A., S. Kass, G. Tanigawa, H.P. Vosberg, W. McKenna,
C.E. Seidman, and J.G. Seidman. 1990. A molecular basis for familial hyper-
trophic cardiomyopathy: a b cardiac myosin heavy chain gene missense mu-
tation. Cell. 62:999–1006.
Geisterfer-Lowrance, A.A.T., M. Christe, D.A. Conner, J.S. Ingwall, F.J.
Schoen, C.E. Seidman, and J.G. Seidman. 1996. A mouse model of familial
hypertrophic cardiomyopathy. Science (Wash. DC). 272:731–734.
Gottshall, K.R., F.F. Hunter, N. Tanaka, K.D. Becker, J. Ross, Jr., and K.R.
Chien. 1997. Ras dependent pathways induce obstructive hypertrophy in
echo-selected mice. Proc. Natl. Acad. Sci. USA. In press.
Grussenmeyer, T., H.T. Scheidtmann, M.A. Hutchinson, W. Eckhart, and G.
Walter. 1985. Complexes of polyoma virus medium T antigen and cellular
proteins. Proc. Natl. Acad. Sci. USA. 82:7952–7954.
Hammer, J.A., B. Bowers, B.M. Paterson, and E.D. Korn. 1987. Complete nu-
cleotide sequence and deduced polypeptide sequence of a nonmuscle myo-
sin heavy chain gene from Acanthamoeba: evidence of a hinge in the rodlike
tail. J. Cell Biol. 105(2):913–925.
Higuchi, R., B. Krummel, and R.K. Saiki. 1988. A general method of in vitro
preparation and specific mutagenesis of DNA fragments: study of protein
and DNA interactions. Nucleic Acids Res. 16:7351–7367.
Hunter, J.J., N. Tanaka, H.A. Rockman, J. Ross, Jr., and K.R. Chien. 1995.
Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hyper-
trophy and selective diastolic dysfunction in transgenic mice. J. Biol. Chem.
270:23173–23178.
Jaenicke, T., K.W. Diederich, W. Haas, J. Schleich, P. Lichter, M. Pfordt, A.The Journal of Cell Biology, Volume 137, 1997 140
Bach, and H.P. Vosberg. 1990. The complete sequence of the human b-myo-
sin heavy chain gene and a comparative analysis of its product. Genomics. 8:
194–206.
Johnson, D.S., N.M. McKenna, and Y. Wang. 1988. Association of microin-
jected myosin and its subfragments with myofibrils in living muscle cells. J.
Cell Biol. 107:2213–2221.
Jurnak, F. 1985. Structure of the GDP domain of EF-Tu and location of the
amino acids homologous to ras oncogene proteins. Science (Wash. DC). 230:
32–36.
Karn, J., S. Brenner, and L. Barnett. 1983. Protein structural domains in the
Caenorhabditis elegans unc-54 myosin heavy chain gene are not separated by
introns. Proc. Natl. Acad. Sci. USA. 80:4253–4257.
Komiyama, M., T. Soldati, P. von Arx, and J.-C. Perriard. 1996. The intracom-
partmental sorting of myosin alkali light chain isoproteins reflects the se-
quence of developmental expression as determined by double epitope tag-
ging competition. J. Cell Sci. 109:2089–2099.
Kubalak, S.W., P.A. Doevendans, H.A. Rockman, J.J. Hunter, N. Tanaka, J.
Ross, Jr., and K.R. Chien. 1996. Molecular analysis of cardiac muscle dis-
eases based on mouse genetics. In Methods in Molecular Genetics, Human
Molecular Genetics; K.W. Adolph, editor. Academic Press, San Diego, CA.
8:470–487.
Lankford, E.B., N.D. Epstein, L. Fananapazir, and H.L. Sweeney. 1995. Abnor-
mal contractile properties of muscle fibers expressing b-myosin heavy chain
gene mutations in patients with hypertrophic cardiomyopathy. J. Clin. In-
vest. 95:1409–1414.
Liew, C.C., M.J. Sole, K. Yamauchi-Takihara, B. Kellam, D.H. Anderson, L.P.
Lin, and J.C. Liew. 1990. Complete sequence and organization of the human
cardiac b-myosin heavy chain gene. Nucleic Acids Res. 18:3647–3651.
Lin, Z., M.-H. Lu, J. Choi, S. Holtzer, C. DiLullo, D.A. Fischman, and H.
Holtzer. 1994. Sequential appearance of muscle-specific proteins in myo-
blasts as a function of time after cell division: Evidence for a conserved myo-
blast differentiation program is skeletal muscle. Cell Motil. Cytoskeleton. 29:
1–19.
Liu, Q.Y., and W.C. Summers. 1988. Site-directed mutagenesis of a nucleotide-
binding domain in HSV-1 thymidine kinase: effects on catalytic activity. Vi-
rology. 163:638–642.
Lu, M.-H., C. DiLullo, T. Schultheiss, S. Holtzer, J.M. Murray, J. Choi, D.A.
Fischman, and H. Holtzer. 1992. The vinculin/sarcomeric–alpha-actinin/al-
pha actin nexus in cultured cardiac myocytes. J. Cell Biol. 117:1007–1022.
Marian, A.J., Q.-T. Yu, D.L. Mann, F.L. Graham, and R. Roberts. 1995. Ex-
pression of a mutation causing hypertrophic cardiomyopathy disrupts sar-
comere assembly in adult feline cardiac myocytes. Circ. Res. 77:98–106.
Maron, B.J. 1988. Historical perspective, nomenclature, and definition. In Car-
diomyopathy Update 2: Hypertrophic Cardiomyopathy. University of To-
kyo Press. Tokyo. pp. 390.
Messerli, J.M., M.E. Eppenberger, B. Rutishauser, P. Schwarb, P. von Arx, S.
Koch-Schneidemann, H.M. Eppenberger, and J.-C. Perriard. 1993. Remod-
eling of cardiomyocyte cytoarchitecture visualized by 3D confocal micros-
copy. Histochemistry. 100:193–202.
Mornet, D., A.A. Bonet, E.E. Audemard, and J. Bonicel. 1989. Functional se-
quences of the myosin head. J. Musc. Res. Cell Motil. 10:10–24.
Pai, E.F., W. Kabsch, U. Krengel, K.C. Holmes, J. John, and A. Wittinghofer.
1989. Structure of the guanine-nucleotide-binding domain of the Ha-ras on-
cogene product p21 in the triphosphate conformation. Nature (Lond.). 341:
209–214.
Poetter, K., H. Jiang, S. Hassanzadeh, S.R. Master, A. Chang, M.C. Dalakas, I.
Rayment, J.R. Sellers, L. Fananapazir, and N.D. Epstein. 1996. Mutations in
either the essential or regulatory light chains of myosin are associated with a
rare myopathy in human heart and skeletal muscle. Nat. Genet. 13:63–69.
Rayment, I., W.R. Rypniewski, K. Schmidt-Base, R. Smith, D.R. Tomchick,
M.M. Benning, D.A. Winkelmann, G. Wesenberg, and H.M. Holden. 1993a.
Three-dimensional structure of myosin subfragment-1: A molecular motor.
Science (Wash. DC). 261:50–58.
Rayment, I., H.M. Holden, M. Whittaker, C.B. Yohn, M. Lorenz, K.C. Holmes,
and R.A. Milligan. 1993b. Structure of the actin-myosin complex and its im-
plications for muscle contraction. Science (Wash. DC). 261:58–65.
Rayment, I., H.M. Holden, J.R. Sellers, L. Fananapazir, and N.D. Epstein. 1995.
Structural interpretation of the mutations in the b-cardiac myosin that have
been implicated in familial hypertrophic cardiomyopathy. Proc. Natl. Acad.
Sci. USA. 92:3864–3868.
Reinstein, J., M. Brune, and A. Wittinghofer. 1988. Mutations in the nucleotide
binding loop of adenylate kinase of Escherichia coli. Biochemistry. 27:4712–
4720.
Rhee, D., J.M. Sanger, and J.W. Sanger. 1994. Ther premyofibril: Evidence for
its role in myofibrillogenesis. Cell Motil. Cytoskeleton. 28:1–24.
Rosenzweig, A., H. Watkins, D.S. Hwang, M. Miri, W. McKenna, T.A. Traill,
J.G. Seidman, C.E. Seidman. 1991. Preclinical diagnosis of familial hyper-
trophic cardiomyopathy by genetic analysis of blood lymphocytes. N. Engl.
J. Med. 325:635–647.
Ruppel, K.M., and J.A. Spudich. 1996. Structure-function studies of the myosin
motor domain: importance of the 50-kDa cleft. Mol. Biol. Cell. 7:1123–1136.
Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Labo-
ratory Manual. Cold Spring Harbor Laboratory, Cold Harbor, NY.
Schultheiss, T., Z.-X. Lin, M.H. Lu, J. Murray, D.A. Fischman, K. Weber, T.
Masaki, M. Imamura, and H. Holtzer. 1990. Differential distribution of sub-
sets of myofibrillar proteins in cardiac nonstriated and striated myofibrils. J.
Cell Biol. 110:1159–1172.
Soldati, T., and J.-C. Perriard. 1991. Intracompartmental sorting of essential
myosin light chains: molecular dissection and in vivo monitoring by epitope
tagging. Cell. 66:277–289.
Strehler, E.E., M.A. Strehler-Page, J.-C. Perriard, M. Periasamy, and B. Nadal-
Ginard. 1986. Complete nucleotide and encoded amino acid sequence of a
mammalian myosin heavy chain gene. Evidence against intron-dependent
evolution of the rod. J. Mol. Biol. 190:291–317.
Squire, J.M. 1986. Muscle: design, diversity and disease. Benjamin/Cummings
Publishing Co., Menlo Park, CA.
Sweeney, H.L., A.J. Straceski, L.A. Leinwand, B.A. Tikunov, and L. Faust.
1994. Heterologous expression of a cardiomyopathic myosin that is defective
in its actin interaction. J. Biol. Chem. 269:1603–1605.
Thierfelder, L., H. Watkins, C. MacRae, R. Lamas, W. McKenna, H.P. Vos-
berg, J.G. Seidman, and C.E. Seidman. 1994. Alpha-tropomyosin and car-
diac troponin T mutations cause familial hypertrophic cardiomyopathy: a
disease of the sarcomere. Cell. 77:701–712.
von Arx, P., S. Bantle, T. Soldati, and J.-C. Perriard. 1995. Dominant negative
effect of cytoplasmic actin isoproteins on cardiomyocyte cytoarchitecture
and function. J. Cell Biol. 6:1759–1773.
Walker, J.E., M. Saraste, M.J. Runswick, and N.J. Gay. 1982. Distantly related
sequences in the alpha and beta subunits of ATP synthase, myosin, kinases
and other ATP-requiring enzymes and a common nucleotide binding fold.
EMBO (Eur. Mol. Biol. Organ.) J. 1(8):945–951.
Warrick, H.M., and J.A. Spudich. 1987. Myosin structure and function in cell
motility. Annu. Rev. Cell Biol. 3:379–421.
Warrick, H.M., A. De Lozanne, L.A. Leinwand, and J.A. Spudich. 1986. Con-
served protein domains in a myosin heavy chain gene from Dictyostelium
discoideum. Proc. Natl. Acad. Sci. USA. 83:9433–9437.
Watkins, H., T. Rosenzweig, D.S. Hwang, T. Levi, W. McKenna, C.E. Seidman,
and J.G. Seidman. 1992. Characteristics and prognostic implication of myo-
sin missense mutations in familial hypertrophic cardiomyopathy. N. Engl. J.
Med. 326:1106–1114.
Watkins, H., D. Conner, L. Thierfelder, J.A. Jarcho, C. MacRae, W.J. Mc-
Kenna, B.J. Maron, J.G. Seidman, and C.E. Seidman. 1995a. Mutations in
the cardiac myosin binding protein-C gene on chromosome 11 cause familial
hypertrophic cardiomyopathy. Nature Genet. 11:434–437.
Watkins, H., W.J. McKenna, L. Thierfelder, H.J. Suk, R. Anan, A. O’Dono-
ghue, P. Spirito, A. Matsumori, C.S. Moravec, J.G. Seidman, and C.E.
Seidman. 1995b. Mutations in the genes for cardiac troponin T and alpha
tropomyosin in hypertrophic cardiomyopathy. N. Engl. J. Med. 332:1058–
1064.
Wilson, I.A., H.L. Niman, R.A. Houghten, A.R. Cherenson, M.L. Connolly,
and R.A. Lerner. 1984. The structure of an antigenic determinant in a pro-
tein. Cell. 37:767–778.
Yanagisawa, M., Y. Hamada, Y. Katsuragawa, M. Imamura, T. Mikawa, and T.
Masaki. 1987. Complete primary structure of vertebrate smooth muscle my-
osin heavy chain deduced from its complementary DNA sequence. Implica-
tions on topography and function of myosin. J. Mol. Biol. 198:143–157.
Zhu, H., A.V. Garcia, R.S. Ross, S.M. Evans, and K.R. Chien. 1991. A con-
served 28-base-pair element (HF-1) in the rat cardiac myosin light-chain-2
gene confers cardiac-specific and alpha-adrenergic-inducible expression in
cultured neonatal rat myocardial cells. Mol. Cell. Biol. 11:2273–2281.